Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KNSA logo KNSA
Upturn stock ratingUpturn stock rating
KNSA logo

Kiniksa Pharmaceuticals Ltd (KNSA)

Upturn stock ratingUpturn stock rating
$28.04
Last Close (24-hour delay)
Profit since last BUY1.08%
upturn advisory
Consider higher Upturn Star rating
BUY since 40 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: KNSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $38

1 Year Target Price $38

Analysts Price Target For last 52 week
$38Target price
Low$17.82
Current$28.04
high$30.69

Analysis of Past Performance

Type Stock
Historic Profit -34.57%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.02B USD
Price to earnings Ratio -
1Y Target Price 38
Price to earnings Ratio -
1Y Target Price 38
Volume (30-day avg) 6
Beta 0.05
52 Weeks Range 17.82 - 30.69
Updated Date 06/30/2025
52 Weeks Range 17.82 - 30.69
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.24

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-06-05
When Before Market
Estimate 0.2833
Actual 0.11

Profitability

Profit Margin -3.52%
Operating Margin (TTM) 9.63%

Management Effectiveness

Return on Assets (TTM) -1.77%
Return on Equity (TTM) -3.81%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1760681655
Price to Sales(TTM) 4.2
Enterprise Value 1760681655
Price to Sales(TTM) 4.2
Enterprise Value to Revenue 3.66
Enterprise Value to EBITDA -44.93
Shares Outstanding 42336200
Shares Floating 36280435
Shares Outstanding 42336200
Shares Floating 36280435
Percent Insiders 3.83
Percent Institutions 96.14

Analyst Ratings

Rating 3
Target Price 38
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Kiniksa Pharmaceuticals Ltd

stock logo

Company Overview

overview logo History and Background

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with debilitating diseases with unmet medical need. Founded in 2015.

business area logo Core Business Areas

  • Immunology: Focuses on developing therapies for inflammatory and autoimmune diseases.
  • Rare Diseases: Develops treatments for rare and often genetic disorders.

leadership logo Leadership and Structure

The leadership team is headed by the CEO. The company has functional departments covering research, development, commercial, and administrative operations. Specific names and details would require accessing current public filings or their website.

Top Products and Market Share

overview logo Key Offerings

  • Mavrilimumab (formerly known as MAV, now discontinued): An anti-GM-CSF receptor alpha monoclonal antibody. The program was terminated. Competing products include TNF inhibitors and other biologics targeting inflammatory pathways from companies like AbbVie, Amgen, and Novartis.
  • Rilonacept (ARCALYST): Recombinant fusion protein that blocks IL-1. Used for cryopyrin-associated periodic syndromes (CAPS). It is now owned by Regeneron. Competitors include Ilaris (Novartis) which also targets IL-1.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Innovation and patent protection are critical for success.

Positioning

Kiniksa focuses on niche markets within immunology and rare diseases. Their success depends on clinical trial outcomes and regulatory approvals.

Total Addressable Market (TAM)

The TAM for inflammatory and rare diseases is significant, estimated in the billions of dollars annually. Kiniksa's positioning depends on the specific indications they target and their ability to penetrate those markets.

Upturn SWOT Analysis

Strengths

  • Focus on specific therapeutic areas
  • Innovative pipeline (if applicable, details needed from current status)
  • Experienced management team

Weaknesses

  • Reliance on clinical trial success
  • Competition from larger pharmaceutical companies
  • Financial resources relative to larger companies

Opportunities

  • Expanding into new indications
  • Partnering with larger pharmaceutical companies
  • Acquiring new technologies or assets

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from biosimilars or generics
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • AMGN
  • NVS

Competitive Landscape

Kiniksa faces competition from larger, more established pharmaceutical companies with greater resources. Their competitive advantage lies in their focus on specific therapeutic areas and their innovative pipeline.

Growth Trajectory and Initiatives

Historical Growth: Historical growth depends on product approvals and commercial success. This would require a review of historical financial statements.

Future Projections: Future growth projections would depend on analyst estimates, which are based on pipeline potential and market opportunities.

Recent Initiatives: Recent initiatives would include any new clinical trials, regulatory filings, or partnerships.

Summary

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on unmet medical needs and it is small in comparison to other bigger companies, which can be a strength and a weakness. It needs to be aware of its competitors and continue innovating to develop therapeutic medicines for debilitating diseases. Kiniksa Pharmaceuticals Ltd has not paid dividends to shareholders.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports
  • Financial News Outlets

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Kiniksa Pharmaceuticals Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2018-05-24
CEO & Chairman of the Board Mr. Sanj K. Patel
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 315
Full time employees 315

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.